Modality
Peptide
MOA
TROP-2 ADC
Target
IL-23
Pathway
Proteasome
Huntington's
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Jul 2028
Phase 1Current
NCT05088706
770 pts·Huntington's
2024-10→2025-05·Terminated
NCT05903973
251 pts·Huntington's
2021-10→2028-07·Active
1,021 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2610mo agoInterim· Huntington's
2028-07-032.3y awayInterim· Huntington's
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Active
P1
Termina…
Catalysts
Interim
2025-05-26 · 10mo ago
Huntington's
Interim
2028-07-03 · 2.3y away
Huntington's
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05088706 | Phase 1 | Huntington's | Terminated | 770 | HbA1c |
| NCT05903973 | Phase 1 | Huntington's | Active | 251 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| GMA-5010 | Genmab | Phase 3 | JAK2 | |
| INC-1582 | Incyte | Phase 1/2 | APOC3 | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 | |
| Gelisertib | Samsung Biologics | Approved | IL-23 |